Reading SNMMI 2026 as an Operator: Three Contrarian Positions to Test on the Floor

Byron Fitzgerald | Founder, ProGen Search | May 2026

Introduction: The Conference and the Conversation Underneath It

SNMMI 2026 opens at the Los Angeles Convention Center on 30 May and runs through 02 June. Roughly 250 exhibitors will fill the floor. Clinicians will work the symposia. The press will cover the Phase 3 readouts. None of that captures the commercial conversation that actually matters.

For the BD lead, the executive, and the investor walking that floor, the work is not parsing efficacy data. It is reading where capital, manufacturing, and channel position are converging or diverging, and where the consensus has mis-priced specific aspects of either.

This article frames three contrarian positions worth testing in booth conversations. None of the three requires a new data point. The data already exists. All three require a different lens, the one that prices capacity, supply geography, and channel position rather than the molecular profile in isolation.

This is the lens we built the ProGen SNMMI 2026 Field Guide around. The article below is a public extract from that work.

1. The Lens: Capacity Over Chemistry

The dominant analytical frame in radiopharma reporting starts with the molecule. The target, the chelator, the warhead, the half-life. From there it moves to the clinical data, then to deal valuation, then to a sentence or two on supply.

The order is backwards.

A commercial operator working in the sector for the last 24 months has watched repeatedly as molecular advantage failed to convert into commercial position because the supply geography, the manufacturing physics, or the channel architecture sat in the way. The molecule is licensable. The isotope is contestable. What is increasingly hard to replicate is the grid: the manufacturing sites, the radiopharmacy network, the cold-chain logistics, the regulatory clearances, and the named operators with the credentials to run any of it.

Reading SNMMI 2026 with the grid as the unit of analysis flips which booths matter, which sessions matter, and which deals to take seriously. Capacity over chemistry is not a slogan. It is the working assumption underneath every commercial position discussed below.

2. Observation 1: The Aktis IPO Sets the New Floor on Alpha-Emitter Assets

Aktis priced 17.65 million shares at USD 18.00 on 8 January 2026, raising USD 317.7 million in gross proceeds. The company has no Phase 2 efficacy data, no human dosimetry readouts on its lead Nectin-4 and B7-H3 Ac-225 conjugates, and a pre-IPO licensing relationship with Lilly that gave Lilly anchor rights to part of the platform. The deal cleared at full size with strong syndicate support.

The signal that most readers will miss: public-market investors are willing to fund Ac-225 conjugate platforms at scale on platform thesis alone, without efficacy data, and even where the largest pharma operator already holds rights of first refusal. That re-rates the BD value of every non-PSMA actinium platform in the field without the field gaining a single data point.

Two consequences follow directly.

First, the asking price for second-tier alpha-emitter assets at the next licensing round will sit measurably above where it sat in Q4 2025. BD teams negotiating against an Ac-225 conjugate counterparty between now and the next funding cycle should benchmark to Aktis, not to the prior comparables.

Second, the supply constraint becomes more binding. More funded programmes chasing the same Ac-225 production base means the actinium CEO panel at Symposium 18 is the more material event of SNMMI 2026 than any individual sponsor’s Phase 3 update. If you are doing business development on a TAT asset and you are not in that room or working the conversation around it, you are reading the wrong session.

The position to test on the floor: ask any actinium-platform BD lead what their post-Aktis floor is, and price the answer against the deal architecture rather than the molecule.

3. Observation 2: The Pb-212 Capacity Build Is Larger and Earlier-Stage Than the Field Appreciates

The Ac-225 capacity coverage over the last 12 months has crowded out the parallel Pb-212 story. The build underneath it is substantial and worth pricing properly.

Orano Med is constructing the ATEF facility in France for thorium-228 precursor, targeting 100,000 doses annually within ten years with commissioning scheduled for 2027. This is the largest disclosed Pb-212 capacity project globally. NRG PALLAS and TAG1 have announced expanded European Pb-212 supply on top of that. AdvanCell raised USD 112 million in a Series C on 3 February 2025 to scale Pb-212 manufacturing in Australia.

The collective build is sized for a clinical pipeline that does not yet exist at Phase 3 scale.

The consensus read at SNMMI 2026 will frame Ac-225 as the alpha-emitter story and Pb-212 as the smaller adjacent narrative. The capacity numbers say something different. Pb-212 supply infrastructure is being built ahead of clinical demand by sponsors with multi-decade industrial track records, not by venture-backed startups testing the thesis.

For BD readers looking at any Pb-212 asset, the right question is not whether supply will exist. It is whether the sponsor has secured allocation before the Phase 3 pipeline forms. For investors, the Orano Med ATEF commissioning timeline (2027) is the binding event date for the entire Pb-212 commercial cohort.

The 10.6-hour half-life imposes a tight distribution constraint. The supply geography will be built around overnight distribution from a small number of central nodes. Whoever secures slots at those nodes wins the modality.

The position to test on the floor: ask Pb-212 sponsors at the meeting where their precursor supply allocation sits in the Orano Med or NRG PALLAS queue. The answer separates the credible commercial paths from the optimistic ones.

4. Observation 3: Bracco / Blue Earth Is the PSMA Name the Consensus Underweights

Blue Earth published a prospective, intra-patient head-to-head comparator study of POSLUMA (flotufolastat F 18) versus piflufolastat F 18 on 27 February 2026. The study, conducted in 55 men with biochemical recurrence of prostate cancer, showed bladder SUVmean of 10.9 versus 29.0 (median paired difference 15.1, p<0.001). The 15.1 figure is the patient-level median paired difference, not the subtraction of medians.

Blue Earth’s speaker stack at Symposium 3 includes K. Elizabeth Hawk (UCSD and Stanford) and Brian Helfand, Division Chief of Urology at Northshore Hospital and Associate CSO at Endeavor Health. The Helfand affiliation is the deliberate signal. Blue Earth is moving the agent-selection decision upstream from the radiologist read to the urologist referral order.

Lantheus’s PYLARIFY TruVu approval on 6 March 2026 defends batch economics and the radiologist read. It does not defend the referral order.

PSMA PET agent selection is two markets layered on top of each other. One downstream, the radiologist preference, where Lantheus holds the install base. One upstream, the urologist preference, where Blue Earth is now contesting with the bladder data and a urologist KOL stack. Bracco’s separate ownership of Blue Earth Therapeutics, with worldwide rights to rhPSMA, puts the same parent in front of both the diagnostic and the theranostic conversation in prostate cancer.

For investors, the consensus underweight on Bracco’s PSMA exposure misses the urology channel position. For BD readers, the Bracco group is a credible second PSMA imaging franchise with an emerging theranostic adjacency, not a residual share-taker behind Lantheus.

The position to test on the floor: attend Symposium 3 with the urology question, not the imaging question. The strategic move Blue Earth is making is visible only if you ask urologists, not radiologists, who they want ordering the scan.

5. The Thread Across All Three

The consensus view at SNMMI 2026 will be: PSMA scales, ACTION-1 matters, supply is constrained. All three observations above accept the supply constraint as given, and argue that the consensus has mis-valued specific aspects of it.

The Aktis read-through re-rates the alpha floor. The Pb-212 capacity build is larger and earlier-stage than the field appreciates. The POSLUMA bladder data re-rates the urology referral channel.

None of these require a new data point.

All three require a different lens.

The work for the operator on the floor is to walk the booths, attend the sessions, and pressure-test which of these positions the consensus has actually priced. The answers are not in the press releases. They are in the conversations.

6. What This Means for the Floor

A commercial walk of SNMMI 2026 with this lens looks different from a clinical walk of the same conference.

The booths to prioritise are the manufacturing capacity providers, the isotope suppliers, the radiopharmacy networks, and the small group of integrators whose grid position is being re-rated alongside the deal flow. The booths to deprioritise are the late-stage clinical sponsors who will dominate press coverage but whose commercial trajectory is already priced.

The sessions to prioritise are the supply-side panels (the actinium CEO panel, the Pb-212 industrial briefings), the channel-positioning symposia where urologists and radiologists are debating ordering authority, and the regulatory sessions that govern multi-jurisdictional manufacturing. The sessions to deprioritise are the Phase 3 readouts that have already been press-released.

The people to prioritise are the BD leads, the commercial heads of supply, the regulatory operators with multi-modality exposure, and the investors whose theses are anchored on grid position rather than molecular advantage. The people to deprioritise are the clinicians and clinical leadership whose conversations will be dominated by efficacy comparisons that do not move the BD pipeline.

The side events matter. The dinners matter. The hotel geography matters. Most of the unbadged conversations that price the alpha and beta deal book for Q3 and Q4 2026 will happen in the hotel bars between Convention Center close and the next morning’s symposia. Walk the floor with that in mind.

7. The Field Guide

We have published the full commercial read in a 70-page Field Guide for operators going to LA. It ranks the twenty BD booths that matter most by commercial utility, not by market capitalisation, with the conversation worth having at each one and the named people on site. It identifies the ten investor booths with live catalysts. It maps the Ac-225 capacity, separating announced commitments from validated supply. It covers the supply picture for Lu-177, Pb-212, and Cu-67. It directories the 250 exhibitors with operator-grade reads on each. It covers the side events, dinners, and hotel geography where the unbadged conversations happen. And it lays out the 90-day catalysts watchlist that extends the read past LA.

Built for the BD lead, the executive, and the investor who has to walk the floor and act on all of it at once. Not for clinicians.

Single-user licence: USD 245. Corporate licence (unlimited internal distribution at one company): USD 1,495.

The full ProGen SNMMI 2026 Field Guide is available here.

A free 10-page preview, containing the three contrarian observations in full plus the table of contents for the full guide, is available in our Intelligence Vault.

Byron Fitzgerald is the Founder of ProGen Search Limited, a specialist executive search and market intelligence firm focused on radiopharma, CDMO, ADC, cell and gene therapy, and adjacent regulated bio-manufacturing. ProGen Search places the leadership talent discussed in this article. To commission custom intelligence or discuss a senior search mandate, write to byron.fitzgerald@progensearch.com.